Introduction {#sec1}
============

In most vertebrates, the process of myogenic differentiation entails the withdrawal of precursors from the cell cycle, followed by their fusion into myotubes. The multinucleate state is characterized by a permanent postmitotic arrest, which renders the myotubes unable to respond to proliferative cues ([@bib18; @bib26]). In contrast, salamander myotubes remain responsive to such cues, being able to re-enter the cell cycle upon serum stimulation in culture ([@bib20]) or after implantation within regenerating structures ([@bib10]).

In salamander (*Notophthalmus viridescens*) A1 myotubes ([@bib4]), serum stimulation induces a reprogramming process that includes partial dedifferentiation, as suggested by the downregulation of the myogenic gene *Myf5* ([@bib7]), and re-entry into the cell cycle, which is also considered an aspect of dedifferentiation. The latter depends on the phosphorylation of Rb ([@bib20]) and the downregulation of p53 activity ([@bib30]). The serum component that triggers these responses is not a conventional growth factor but an as-yet-unidentified thrombin-activated serum component that acts as a mitogen for myotubes, but not for mononucleate precursors ([@bib13; @bib19; @bib21]). Even though mammalian myotube nuclei cannot be reprogrammed upon exposure to this factor ([@bib13]), they are able to re-enter the cell cycle after forming heterokaryons with salamander myotubes ([@bib25]). This suggests that even when the initial response may be different, part of the pathway leading to serum-mediated reprogramming is conserved. Both the identity of the serum factor and the signaling pathways driving the reversal of the differentiated state in regeneration-competent salamander cells remain unknown, although extensive efforts to identify the serum factor are ongoing ([@bib19]).

In proliferating cells, the extracellular signal-regulated kinase (ERK) family of mitogen-activated protein kinases (MAPKs) plays a critical role in driving cell-cycle progression in a variety of cell types ([@bib1; @bib2; @bib15; @bib27; @bib28]). In fibroblasts, sustained ERK activation is required for successful S phase progression by promoting the downregulation of antiproliferative genes during G1 phase and controlling the state of Rb phosphorylation ([@bib28]). Hence, it is possible that ERK activation plays a role during the reprogramming of differentiated salamander cells. Herein, we have tested this hypothesis using the salamander A1 cell line as a model for serum-induced reprogramming.

Results and Discussion {#sec2}
======================

Sustained ERK Activation in Cell-Cycle Re-entry of Salamander Myotubes {#sec2.1}
----------------------------------------------------------------------

Serum stimulation of A1 myotubes triggers an early activation of the ERK pathway, which is sustained for up to 48 hr post stimulation ([Figures 1](#fig1){ref-type="fig"}A and 1B). This is accompanied by a long-term increase in the protein levels of c-FOS ([Figure S1](#app3){ref-type="sec"} available online), a sensor for ERK signal duration ([@bib15]). Other MAPK pathways are also activated, albeit to a lesser extent, including the stress-related MAPKs c-Jun N-terminal kinase (JNK) and p38 ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#app3){ref-type="sec"}). Therefore, we asked whether any of these pathways are required for myotube S phase re-entry following serum stimulation. The administration of specific inhibitors of ERK (U0126), JNK (SP600125), and p38 (506126) kinase activation ([Figure S1](#app3){ref-type="sec"}), alongside serum stimulation, leads to differential disruption of both Rb phosphorylation ([Figures 1](#fig1){ref-type="fig"}C and [S1](#app3){ref-type="sec"}) and S phase re-entry ([Figures 1](#fig1){ref-type="fig"}D and [S1](#app3){ref-type="sec"}) depending on the targeted pathway. Inhibition of the JNK pathway leads to a 50% reduction in both myotube Rb phosphorylation and S phase re-entry, while disruption of the p38 MAPK not only does not impair these processes but also significantly enhances cell-cycle re-entry ([Figure 1](#fig1){ref-type="fig"}D). Remarkably, the inhibition of ERK signaling severely impairs both processes, suggesting that the activation of the ERK pathway is critical for the cell-cycle re-entry of salamander myotubes.

In a variety of mammalian contexts, it is the sustained activation of ERK signaling that promotes cell proliferation ([@bib17; @bib27; @bib28]). To test whether sustained ERK activation mediates the cell-cycle aspects of salamander myotube reprogramming, we incubated A1 myotubes with serum and inhibited ERK signaling at different times post stimulation ([Figure 1](#fig1){ref-type="fig"}E). ERK inhibition, even at 24 hr post stimulation, has a negative effect on Rb phosphorylation ([Figure 1](#fig1){ref-type="fig"}F). This suggests that the sustained, but not transient, activation of the ERK pathway is necessary for cell-cycle re-entry of salamander myotubes.

Several isoforms of ERK MAPKs exist, with ERK1 and its close relative ERK2 mediating cell-cycle progression in a variety of cell types ([@bib29]). The ERK inhibitor used in this study inhibits the activation of ERK1/2 but can also have effects on ERK5/big MAPK 1 (BMK1) signaling ([@bib9]). Hence, we used a specific BMK1 inhibitor to dissect which of the ERK MAPK pathways mediates the myotube response to serum. As seen in [Figures 1](#fig1){ref-type="fig"}C and 1D, the inhibition of BMK1 does not impair Rb phosphorylation or S phase re-entry but significantly enhances these processes. While the general ERK inhibitor decreases S phase re-entry in both myotubes and mononucleates, the BMK1 inhibitor has a negative effect on mononucleates but a positive one on myotubes ([Figures 1](#fig1){ref-type="fig"} and [S1](#app3){ref-type="sec"}). This suggests that activation of both ERK1/2 and ERK5 is required for the proliferation of mononucleates but only ERK1/2 activation is necessary for S phase re-entry in myotubes. The positive effect of BMK1 inhibition on myotube cell-cycle re-entry is likely due to its negative effect on mononucleate proliferation, as it is known that the percentage of myotubes in S phase is inversely proportional to the amount of mononucleates in their vicinity ([@bib20]). Indeed, the inhibition of BMK1 combined with the addition of 30% confluent mononucleates abrogates the effect of ERK5 inhibition and impairs myotube S phase re-entry ([Figure S1](#app3){ref-type="sec"}).

Sustained activation of ERK signaling has been shown to promote the downregulation of *Gadd45*, a classical p53 target ([@bib28]). Furthermore, we have recently shown that the downregulation of p53 activity is a critical step during A1 myotube cell-cycle re-entry ([@bib30]). To test whether p53 downregulation is promoted by ERK signaling, we compared the effects on Rb phosphorylation and S phase re-entry caused by the stabilization of p53 using nutlin3a ([@bib23]), the inhibition of ERK activation, or a combination of both. All three treatments affected both processes equally ([Figures 1](#fig1){ref-type="fig"}G and 1H) at the mononucleate or myotube level, suggesting that the downregulation of p53 activity and the activation of ERK signaling form part of the same pathway. We additionally observed that while treatment of myotubes with the p53 inhibitor α-pifithrin did not affect Rb phosphorylation or cell-cycle re-entry, the combined inhibition of ERK signaling and p53 had a negative effect on this processes. However, the joint inhibition of ERK and p53 significantly increased the percentage of myotubes positive for Rb phosphorylation and re-entering the cell cycle, when compared with the inhibition of ERK signaling on its own ([Figures 1](#fig1){ref-type="fig"}G and 1H). This suggests that ERK signaling is required for cell-cycle re-entry by, at least in part, promoting the downregulation of p53 activity. To test this further, we investigated the effect of inhibiting different MAPKs on the regulation of *Gadd45* gene expression by in situ hybridization. ERK inhibition abrogated the downregulation of *Gadd45* induced by serum stimulation ([Figure 1](#fig1){ref-type="fig"}I), suggesting that the activation of the ERK pathway promotes cell-cycle re-entry in salamander myotubes by downregulating p53 activity.

ERK Activation Promotes Phenotypic Changes in Salamander Myotubes {#sec2.2}
-----------------------------------------------------------------

A second aspect of the response to serum stimulation in salamander myotubes is the promotion of transcriptional changes that lead to partial dedifferentiation. As ERK activation is required at such an early stage of the response, it is plausible that it contributes to the promotion of dedifferentiation as well as cell-cycle progression. To address this possibility we cloned the newt homolog of the muscle-specific gene *Sox6* ([@bib5]) ([Figure S2](#app3){ref-type="sec"}) and examined its expression in purified myotube cultures. While serum stimulation leads to a 50% reduction of the relative levels of Sox6 ([Figure 2](#fig2){ref-type="fig"}A), ERK inhibition abrogates this effect, suggesting that the downregulation of *Sox6* upon serum stimulation is dependent on ERK activation. This observation is consistent with a previous study suggesting that ERK activation drives the dedifferentiation of rodent Schwann cells ([@bib6]). While the expression of *Sox6* changed upon serum stimulation, we did not detect any changes in the protein levels of muscle-specific myosin heavy chain under similar conditions ([Figure 2](#fig2){ref-type="fig"}C). This is consistent with the notion that serum promotes a limited dedifferentiation process in regeneration-competent salamander myotubes.

Furthermore, we noticed that there are large-scale epigenetic changes in the A1 myotubes following serum stimulation. Immunostaining against the repressive histone mark dimethyl H3K9 ([@bib8]) revealed a decrease in signal intensity in myotubes upon serum stimulation, consistent with previous observations ([@bib13]). Interestingly, this decrease is abrogated only by ERK, but not by JNK or BMK1 inhibition ([Figure 2](#fig2){ref-type="fig"}B). Western blot analysis of purified myotube extracts indicates that there is a 50% decrease in dimethyl H3K9 upon serum stimulation but only a 20% decrease when ERK signaling is inhibited ([Figure 2](#fig2){ref-type="fig"}C). This is particularly interesting for two reasons. First, the demethylation of H3K9 at E2F-regulated promoters is required for the progression into S phase ([@bib16]). Second, H3K9 demethylation is required for the expression of pluripotency-associated genes and the maintenance of embryonic stem cells ([@bib12]).

In the light of these observations, it is possible that the changes in H3K9 demethylation, which we show to be dependent on ERK activation, generate a favorable environment for altering gene expression in the direction of partial dedifferentiation and cell-cycle progression in regeneration-competent cells.

Lack of Sustained ERK Activation in Regeneration-Incompetent Mammalian Myotubes {#sec2.3}
-------------------------------------------------------------------------------

While salamander myotubes are able to respond to serum stimulation by promoting a signaling cascade leading to partial dedifferentiation and cell-cycle re-entry, mammalian myotubes are unable to do so ([@bib20]). Nevertheless, the latter appear to have retained some responsiveness, as serum stimulation ([@bib22]) or incubation with partially purified serum factor preparations ([@bib13]) leads to the upregulation of immediate-early proliferative response genes such as *c-fos*. However, the subsequent steps in the pathway leading to reprogramming do not take place. In the light of our observations, this suggests that altered or absent ERK activation could underlie the lack of responsiveness found in mammalian myotubes.

We explored this possibility using the murine myogenic cell line Pmi28 ([Figure 3](#fig3){ref-type="fig"}A), which can be induced to form myotubes that cannot dedifferentiate or re-enter the cell cycle upon serum stimulation ([@bib3]). Remarkably, we found that serum stimulation of Pmi28 myotubes leads to transient ERK1/2 activation, which peaks at 1 hr post induction and returns to baseline in approximately 3 hr ([Figures 3](#fig3){ref-type="fig"}B and 3C). In this system, the intensity of ERK activation is considerably lower than in the induced salamander myotubes ([Figure 3](#fig3){ref-type="fig"}C). Furthermore, unlike A1 myotubes, stimulated Pmi28 myotubes do not activate JNK and do not exhibit any changes in the total amounts of the repression marker dimethyl H3K9 ([Figure 3](#fig3){ref-type="fig"}D). However, serum stimulation promotes the upregulation of c-FOS and an increase in cyclin D1 and D3, which depend on the transient activation of ERK ([Figures 3](#fig3){ref-type="fig"}D and 3E). This suggests that the transient response to serum previously observed in mammalian myotubes is mediated by ERK signaling. Nonetheless, consistent with previous observations ([@bib13; @bib22]), we did not observe any changes in late proliferative genes such as Cyclin E2 and PCNA ([Figure 3](#fig3){ref-type="fig"}E). Together, these observations suggest that the extent of ERK signaling could underlie differences in regenerative capabilities between salamander and mammalian cells.

Finally, we tested whether the artificial promotion of ERK activation could promote cell-cycle re-entry in this system. Overexpression of two different constitutively active ERK activator kinase 1 (MEK1) mutants, MEK1-R4F and MEK1^S218E/S222D^ ([@bib14]), does not lead to S phase re-entry in Pmi28 myotubes. Such failure in promoting cell-cycle progression could be attributed to the lack of coactivation of other MAPKs (e.g., JNK), the presence of epigenetic factors in mammalian myotubes that stabilize the differentiated state, or the intrinsic limitations of the overexpression system, which does not permit an exact mimicry of the required kinetics of ERK activation. However, constitutive ERK activation by overexpression of the MEK1 mutants does promote an increase in the protein levels of c-FOS and, importantly, the late proliferative gene PCNA ([Figure 3](#fig3){ref-type="fig"}F). These changes could result from either the sustained activation of ERK signaling or the transient elevation of phosphorylated ERK (pERK) levels upon constitutive expression of the mutants. The induction of untransfected Pmi myotubes with 20% serum leads to a pERK/ERK ratio of 0.87 ± 0.13. In contrast, the overexpression of MEK1-R4F and MEK1^S218E/S222D^ leads to lower pERK/ERK ratios (0.34 ± 0.05 and 0.53 ± 0.07, respectively, corrected for total protein load); however, these are sustained over time. Hence, our results suggest that the promotion of sustained ERK activation can further the progression of the cell-cycle re-entry program in mammalian myotubes.

A Model for the Role of ERK Signaling during the Reprogramming of Postmitotic Differentiated Cells {#sec2.4}
--------------------------------------------------------------------------------------------------

We propose that in regeneration competent salamander myotubes---and possibly other cell types---an as-yet-unidentified thrombin-activated serum factor triggers sustained activation of ERK signaling ([Figure 3](#fig3){ref-type="fig"}G). Such activation leads to the downregulation of p53 activity, which facilitates cell-cycle re-entry via Rb phosphorylation, and promotes alterations in the gene expression landscape that could favor both partial dedifferentiation and cell-cycle re-entry. ERK activation could also crosstalk with the JNK and p38 stress-related signaling cascades, for example by modulating the apoptotic response mediated by these kinases. In contrast, regeneration-incompetent mammalian cells are incapable of inducing sustained ERK activation, most likely due to a lack of an upstream receptor or signaling component, and are therefore unable to undergo reprogramming.

In this study, we show that sustained ERK activation is required for the promotion of phenotypic changes suggestive of partial dedifferentiation and, critically, for cell-cycle re-entry in salamander myotubes. It remains an issue whether other muscle-specific genes are downregulated upon serum stimulation and whether this partial dedifferentiation is dependent on cell-cycle re-entry. In this regard, an earlier study showed that cellularization ([@bib24]), another index of dedifferentiation, proceeds in the absence of cell-cycle re-entry. Further studies should determine the connection between these processes.

It is particularly interesting that a similar mechanism to that used by proliferating cells following standard growth factor stimulation (sustained ERK signaling) is activated during salamander myotube reprogramming, as the serum factor responsible for triggering this process is not one of the conventional growth factors known to promote proliferation in undifferentiated cells ([@bib19; @bib21]). Indeed, the inhibition of fibroblast growth factor (FGF) and VEGF, growth factors that elicit sustained ERK1/2 signaling in a range of proliferating cell types, does not perturb either ERK1/2 or Rb phosphorylation in purified myotubes ([Figure S3](#app3){ref-type="sec"}). Nevertheless, the use of a general receptor tyrosine kinase inhibitor abrogates ERK, JNK, and Rb phosphorylation following serum stimulation, suggesting that a receptor tyrosine kinase is required for the initiation of the reprogramming response. This unidentified RTK may be a target, direct or indirect, of the thrombin-activated serum factor. Further efforts should focus on defining the nature of both the serum factor as well as the RTK, so as to gain a better understanding of the mechanisms regulating the plasticity of the differentiated state in regeneration-competent cells and eventually apply this knowledge in a clinical setting.

Conclusions {#sec3}
===========

Together, our results suggest that the ability to trigger sustained ERK activation may underlie species-specific differences in the generation of cells of regenerative potential. Furthermore, they suggest that current approaches to induce regenerative potential in mammalian systems should consider the manipulation of MAPK signaling, with a focus on the promotion of ERK activation.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

A1 cells were previously derived from newt (*N. viridescens*) limb mesenchyme ([@bib4]). The cells were grown on 0.75% gelatine-coated plastic dishes in minimal essential medium (Gibco) supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco), 25% H~2~O, 2nM L-glutamine (Gibco), 10 μg/ml insulin (Sigma), and 100 U/ml penicillin/ streptomycin (Gibco) in a humidified atmosphere of 2.5% CO~2~ at 25°C. Routine cell subculture was performed as previously described ([@bib11]).

Pmi28 cells were a kind gift from A. Starzinski-Powitz (Goethe Universität, Germany). Mouse Pmi28 cells were grown on BIOCOAT I T-75 flasks (Becton-Dickinson) in F-10 (HAM) media supplemented with 20% FCS (Gibco) and 100 U/ml penicillin/ streptomycin (Gibco) in a humidified atmosphere of 6% CO~2~ at 37°C. Cells were passaged at a 1:10 ratio every 3 days.

Myotube Formation Assay {#sec4.2}
-----------------------

Myogenesis was induced in confluent A1 cells by lowering the fetal calf serum concentration from 10% to 0.25%. Cells were incubated in a humidified atmosphere of 2.5% CO~2~ at 25°C. After 5 days, \>90% of cells fused into multinucleate myotubes as previously described ([@bib11]). Reprogramming was induced by incubating the myotubes in standard growth medium. All inhibitors used in the present manuscript are specified in [Table S1](#app3){ref-type="sec"}.

In Pmi28 cell cultures, myogenesis was induced as previously described ([@bib3]). Cells were plated at high density onto collagen-coated plastic dishes and maintained for 3 days in differentiation media, consisting of Dulbecco's modified Eagle's medium (Gibco) supplemented with 6% horse serum (HS; Sigma) and 100 U/ml penicillin/ streptomycin (Gibco).

Myotube Purification {#sec4.3}
--------------------

Myotubes were trypsinized for 1 min, neutralized with media, and sieved through a 100 μm mesh followed by a 35 μm mesh (Cell MicroSieve; BioDesign Inc. of New York). Myotubes were retained on the 35 μm mesh, washed with media to eliminate mononucleates, and collected from the sieve into dishes precoated with 0.75% gelatin.

Pmi28 myotubes were purified by addition of 50 μM Ara-C (Sigma), which specifically eliminates proliferating cells, to the differentiation media. The purity of the resulting cultures was assessed by fluorescence microscopy following incubation with Hoechst 33258 (2 μg/ml).

Statistical Analysis {#sec4.4}
--------------------

Statistical analyses were performed with Prism 4.0, and unpaired two-tailed t tests were applied unless otherwise stated. Paired two-tailed t tests were carried out to analyze RT-PCR experiments.

Accession Numbers {#app1}
=================

The GenBank accession number for the CDS of *Notophthalmus viridescens Sox6* reported in this paper is [KJ801973](ncbi-n:KJ801973){#intref0010}.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S3, and Tables S1 and S2Document S2. Article plus Supplemental Information
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![Sustained ERK Activation Is Necessary for Cell-Cycle Re-entry of Differentiated, Regeneration-Competent Salamander Myotubes\
(A) Western blot analysis of A1 myotube extracts pre (0.25% FCS) or post serum induction.\
(B) Western blot quantification of phospho protein levels, relative to β-actin, showing the kinetics of ERK and JNK activation upon serum induction.\
(C) Quantification of myotubes exhibiting phosphorylated Rb, following immunostaining 48 hr after serum induction, in the presence of the indicated compounds.\
(D) Quantification of bromodeoxyuridine (BrdU)-positive myotubes, as measured by immunostaining at 72 hr post serum induction, following a BrdU pulse.\
(E) Schematic representation of myotube treatments to test the effect of ERK inhibition in cell-cycle re-entry.\
(F) ERK inhibition at different times after serum induction affects Rb phosphorylation in myotubes, as determined by immunostaining at 72 hr. ^∗∗^ refers to significant differences between 72 hr and 24 hr measurements.\
(G--I) Serum-induced Rb phosphorylation (G) and myotube S phase re-entry (H) are impaired by p53 stabilization, ERK inhibition, or their combined treatment. Insets correspond to Rb phosphorylation (G) or cell-cycle re-entry (H) in myotubes exposed to the indicated treatments. (I) In situ hybridization against the p53 target gene *Gadd45*. ERK inhibition impairs the downregulation of *Gadd45* in A1 myotubes following serum induction.\
Values represent the mean ± SD (B) or mean ± SEM (C--H) (^∗^p \< 0.05, ^∗∗^p \< 0.01); n = 4 (B, F, and I) and n = 5 (C, D, G, and H), where n indicates the number of independent experiments. Scale bar in (I) represents 40 μm.](gr1){#fig1}

![ERK Activation Leads to Downregulation of Muscle-Specific Gene Expression and Promotes Epigenetic Changes during Reprogramming of Salamander Myotubes\
(A) Left: schematic representation of the variation in *Sox6* mRNA levels upon myogenic differentiation. Right: quantitative RT-PCR analysis of *Sox6* (with two different primers, *Sox6* 1 and *Sox6* 2) in RNA extracts from purified A1 myotubes, normalized to *Ef1-α* or *L27*.\
(B) Representative images of myotubes following immunostaining against dimethylated H3K9 and myosin heavy chain (MyHC) 1.5 days after the indicated treatments. Scale bar represents 50 μm.\
(C) Western blot analysis of purified myotube extracts. Note the decrease in dimetH3K9 upon serum induction and its impairment when ERK signaling is inhibited. The relative amount of dimethylated H3K9 was quantified for the indicated treatments.\
Values represent the mean ± SEM (^∗^p \< 0.05); n = 4 (A--C), where n indicates the number of independent experiments.](gr2){#fig2}

![Regeneration-Incompetent Mammalian Myotubes Do Not Trigger Sustained ERK Activation upon Serum Stimulation\
(A) Representative image of Pmi28 myotubes 3 days after myogenesis. Nuclei are stained with Hoechst 33258 (blue). Scale bar represents 100 μm.\
(B, C, and E) Western blot analysis of Pmi28 myotube extracts pre (6% HS) or at different times after induction with 20% FCS.\
(D) Differential kinetics of ERK activation in mammalian versus salamander myotubes at different times after serum induction following western blot quantification of relative levels of phosphorylated ERK.\
(F) Western blot analysis of whole-cell extracts from myotubes overexpressing pnGFPN2 (GFPN2), MEK1-R4F (R4F), and MEK1^S218E/S222D^(SE/SD). The relative amount of c-*fos* and PCNA was quantified for the indicated treatments.\
(G) A model for the role of ERK1/2 activation during serum-induced reprogramming of regeneration-competent salamander myotubes compared to their mammalian counterparts.\
Values represent the mean ± SD (^∗^p \< 0.05, ^∗∗^p \< 0.01); n = 4 (B--F), where n indicates the number of independent experiments.](gr3){#fig3}
